SCHEMBL21604151

SCHEMBL21604151

COC(=O)c1cc(OC2CC2)nn1C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNE1 P24864 6/20 0.39
CDK2 P24941 6/20 0.39
FAAH O00519 2/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
MAPK1 P28482 1/20 0.37
ATM Q13315 1/20 0.37
GSK3B P49841 1/20 0.37
CACNB4 O00305 4/20 0.35
CACNA1A O00555 4/20 0.35
CACNA1G O43497 4/20 0.35
CACNG3 O60359 4/20 0.35
CACNA1F O60840 4/20 0.35
CACNA1H O95180 4/20 0.35
CACNB3 P54284 4/20 0.35
CACNA2D1 P54289 4/20 0.35
CACNG7 P62955 4/20 0.35
CACNA1B Q00975 4/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27415464 0.84 KDM4E (0.46) CCNE1CDK2CA12CA1CA2
SCHEMBL26926850 0.83 CACNB4 (0.51) CACNB4CACNA1ACACNA1GCACNG3CACNA1F
SCHEMBL2512844 0.80 ALDH1A1 (0.47) CCNE1CDK2CA12CA1CA2
SCHEMBL26926863 0.79 PIK3CD (0.48) CACNB4CACNA1ACACNA1GCACNG3CACNA1F
SCHEMBL21597695 0.78 JMJD6 (0.39) FAAHCA12CA1CA2CA9
SCHEMBL2516485 0.78 CA12 (0.44) FAAHCA12CA1CA2CA9
SCHEMBL30722877 0.75 PSMB8 (0.42) CCNE1CDK2FAAHCA12CA1
SCHEMBL17473324 0.75 CA12 (0.41) CA12CA1CA2CA9KDM4E
SCHEMBL15273648 0.75 PSMB8 (0.46) FAAHCA12CA1CA2CA9
SCHEMBL21597813 0.74 PKM (0.41) CA12CA1CA2CA9MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2024-06-25 US disclosed
CN-112566910-A Thiophene derivatives for the treatment of IgE induced diseases UCB生物制药有限责任公司 2021-03-26 CN disclosed
WO-2019243550-A1 THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE UCB Biopharma SRL (BE) 2019-12-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE TSLP, CYSLTR1, CYSLTR2 CCNE1 3088/4885CDK2 4050/4885FAAH 1644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.